Search research articles
Contact Us
Filters
Showing results (141-150 of 186) with videos related to
Page
of 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Cancer Treatment Reviews
|
December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development
R Stahel, J Bogaerts, F Ciardiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2002
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules
A Awada, S Giacchetti, B Gerard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 4, 2014
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer
F Rothé, J-F Laes, D Lambrechts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial
J M N Lopes Cardozo, D Byng, C A Drukker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2001
Phase II study of vinorelbine in patients with androgen-independent prostate cancer
S Oudard, A Caty, Y Humblet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2013
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial
E de Azambuja, D Zardavas, M Lemort, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2008
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial
B C Pestalozzi, P Francis, E Quinaux, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 186) with videos related to
Sort By:
Page
of 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Cancer Treatment Reviews
|
December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development
R Stahel, J Bogaerts, F Ciardiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2002
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules
A Awada, S Giacchetti, B Gerard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 4, 2014
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer
F Rothé, J-F Laes, D Lambrechts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial
J M N Lopes Cardozo, D Byng, C A Drukker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2001
Phase II study of vinorelbine in patients with androgen-independent prostate cancer
S Oudard, A Caty, Y Humblet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2013
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial
E de Azambuja, D Zardavas, M Lemort, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2008
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial
B C Pestalozzi, P Francis, E Quinaux, et al.
Page
of 19